What if a one-time sickle-cell gene cure drops below $200k?
Clean chain: a sub-$200k manufacturing breakthrough for a one-time sickle-cell cure resets rare-disease pricing — bullish the manufacturing/vector-scale enablers and access, but a pricing-power headwind for premium one-shot gene-therapy incumbents (e.g. bluebird/Vertex-CRISPR economics). No tidy macro analogue; closest is the cost-curve collapse in CAR-T/cell manufacturing. Negligible macro signal — the tiny risk-on cascade is immaterial; this is an intra-biotech pricing rotation.
Every number ships with its receipt — the odds, the range, the precedents, and a public grade at Reality Check. The statistical machinery that produces it is proprietary.
The butterfly cascade
How this trigger trickles across markets, left → right — the root shock, its first‑order moves, then the ripple effects. Drag any node; tap a market for its real price history.
Resolution timeline — how this probability is moving
Our model's odds (electric blue) over time vs the market's (Polymarket, amber), from the past toward the 1–3 years horizon. Each dot is a real macro event that nudged the probability — green pushed it up, red pushed it down. Tap a dot for the source. Loading the probability audit trail…
What it would mean
If this plays out, it is a mixed shock. Manufacturing breakthrough drops one-time sickle-cell gene cure under $200k, reshaping rare-disease pricing and payer models. The trigger decomposes into signed root‑shocks — Risk appetite ▲ — which propagate through our causal graph to the markets below.